Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: results from a tertiary center in the contemporary BCG-shortage era.

Jiping Zeng,Joel Funk,Benjamin R Lee,Chiu-Hsieh Hsu,Edward M Messing,Juan Chipollini

Translational andrology and urology（2023）

引用 0|浏览8

暂无评分

摘要

Intravesical gemcitabine for intermediate and high-risk NMIBC in areas where BCG supply is limited was safe and feasible at short-term follow-up. Larger prospective studies are needed to better ascertain the oncologic efficacy of gemcitabine.

查看译文

关键词

cancer,first-line,high-grade,non-muscle,bcg-shortage

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要